SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal

SOMAÍ Pharmaceuticals announces two significant partnerships with Canymed GmbH and Grünhorn, as part of its entry into the German market.

SOMAÍ Pharmaceuticals Unipessoal LDA ("SOMAÍ"), a leading EU-GMP European pharmaceutical and biotech company specializing in the distribution of cannabinoid-containing pharmaceuticals globally, announces two significant partnerships to strengthen its position in the German market.Two-Year Distribution Agreement with Canymed GmbHSOMAÍ Pharmaceuticals has entered into a two-year distribution agreement with Canymed GmbH ("Canymed"), a pharmaceutical wholesaler of medical cannabis and supplies to pharmacies, doctors' practices, and hospitals throughout Germany. This collaboration enables SOMAÍ to leverage Canymed's extensive distribution network to ship its high-quality cannabinoid-based pharmaceutical products to Germany. The partnership aims to meet the growing demand for innovative healthcare solutions in the German market.Co-Branding Agreement with GrünhornSOMAÍ Pharmaceuticals has made another strategic move by partnering with Grünhorn, a leading healthcare brand in the cannabis sector, to create an exclusive co-branded cannabinoid-based pharmaceutical product line in Germany. This line will include various ratios of THC/CBD, including 25:1, 10:10, and 50:1. The collaboration combines SOMAÍ's expertise in creating personalized cannabis-based medications with Grünhorn's commitment to providing the highest quality products in Germany. The exclusive product line is designed to offer patients in Germany a unique range of medicinal cannabis options that cater to their individual needs.10 Million Euro Contract Represents Milestone AchievementThese strategic partnerships result in a 10 million euro contract, highlighting SOMAÍ Pharmaceuticals' impact in Germany. The financial commitment reflects mutual goals."We are excited about the opportunities these partnerships bring to SOMAÍ Pharmaceuticals and our commitment to providing cutting-edge cannabinoid-containing pharmaceuticals to patients globally. The collaborations with Canymed GmbH and Grünhorn Pharmacy underscore our dedication to meeting the evolving healthcare needs in Germany," said Michael Sassano, Founder and CEO of SOMAÍ Pharmaceuticals."Canymed is proud to be partnering with SOMAÍ Pharmaceuticals, contributing to the distribution of advanced pharmaceutical solutions. Together, we look forward to making a positive impact on healthcare in Germany," commented Matthias Fischer, Founder and Managing Director of Canymed."Grünhorn is honored to combine Somai's expertise as a renowned manufacturer of cannabis products with the trust we enjoy as a health brand in the cannabis sector. This partnership aligns with our mission to grant patients access to innovative and effective healthcare options," said Stefan Fritsch, Founder of the Grünhorn-Network.